Previous 10 | Next 10 |
FLORHAM PARK, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has appointed Todd Brann...
Amneal Pharmaceuticals (NYSE: AMRX ) announces the FDA nod for its generic version of Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg. More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Fluphenazine Hydrochloride Tablets ...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2020 financial results on Thursday, August 6, 2020, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time...
Last year I created a public screen on Portfolio123, a web-based subscription service that allows you to backtest screens and ranking systems. It invests in companies in the Russell 3000 that spend heavily on R&D. There were four rules in the screen, but the most important were these: ...
A coalition of 51 attorneys general in the U.S. has filed an antitrust complaint in federal court against 26 companies making generic dermatology drugs and 10 executives at these firms claiming wide-spread price-fixing, marketing allocating and bid-rigging related to over 80 different...
A just-published study in the journal Lancet may dampen the enthusiasm for using chloroquine and hydroxychloroquine to treat COVID-19 patients. More news on: Mylan N.V., Sanofi, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Read more ...
With earnings season in the rear-view mirror for the specialty pharmaceutical sector, J.P. Morgan is updating its positioning on the sector as the COVID-19 pandemic marches on - reiterating its favorites in the area and issuing downgrades to a couple of companies facing challenges. More ne...
Image source: The Motley Fool. Amneal Pharmaceuticals, Inc. (NYSE: AMRX) Q1 2020 Earnings Call May 11, 2020 , 8:30 a.m. ET Operator Continue reading
Amneal Pharmaceuticals Inc. (AMRX) Q1 2020 Earnings Conference Call May 11, 2020 08:30 AM ET Company Participants Tasos Konidaris - SVP and CFO Chirag Patel - Co CEO and President Chintu Patel - Co CEO Conference Call Participants Greg Gilbert - SunTrust Randall Stanicky ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...